BTIG Reiterates Buy on Innoviva, Maintains $42 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.5%

Neg 0% Neu 90.5% Pos 0%

BTIG analyst Julian Harrison reiterates Innoviva (NASDAQ:INVA) with a Buy and maintains $42 price target.

Comments

No comments yet. Be the first!